CN119454706A - 治疗kras相关癌症的方法 - Google Patents

治疗kras相关癌症的方法 Download PDF

Info

Publication number
CN119454706A
CN119454706A CN202411400491.9A CN202411400491A CN119454706A CN 119454706 A CN119454706 A CN 119454706A CN 202411400491 A CN202411400491 A CN 202411400491A CN 119454706 A CN119454706 A CN 119454706A
Authority
CN
China
Prior art keywords
cancer
kras
egfr
compound
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411400491.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·K·尼亚蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan Ann Arbor
Original Assignee
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan Ann Arbor filed Critical University of Michigan Ann Arbor
Publication of CN119454706A publication Critical patent/CN119454706A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202411400491.9A 2019-08-22 2020-08-20 治疗kras相关癌症的方法 Pending CN119454706A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962890119P 2019-08-22 2019-08-22
US62/890119 2019-08-22
CN202080059528.XA CN114286676A (zh) 2019-08-22 2020-08-20 治疗kras相关癌症的方法
PCT/US2020/047090 WO2021034992A1 (en) 2019-08-22 2020-08-20 Method of treating kras-associated cancers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080059528.XA Division CN114286676A (zh) 2019-08-22 2020-08-20 治疗kras相关癌症的方法

Publications (1)

Publication Number Publication Date
CN119454706A true CN119454706A (zh) 2025-02-18

Family

ID=74660044

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411400491.9A Pending CN119454706A (zh) 2019-08-22 2020-08-20 治疗kras相关癌症的方法
CN202080059528.XA Pending CN114286676A (zh) 2019-08-22 2020-08-20 治疗kras相关癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080059528.XA Pending CN114286676A (zh) 2019-08-22 2020-08-20 治疗kras相关癌症的方法

Country Status (11)

Country Link
US (1) US20220273643A1 (https=)
EP (1) EP4017489B1 (https=)
JP (1) JP7602272B2 (https=)
KR (1) KR20220050143A (https=)
CN (2) CN119454706A (https=)
AU (1) AU2020334069B2 (https=)
BR (1) BR112022003165A2 (https=)
CA (1) CA3150759A1 (https=)
IL (1) IL290454B2 (https=)
MX (1) MX2022002108A (https=)
WO (1) WO2021034992A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3849537B1 (en) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Combination therapies
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
EP3849535A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
JP2023553492A (ja) 2020-12-15 2023-12-21 ミラティ セラピューティクス， インコーポレイテッド アザキナゾリン汎ＫＲａｓ阻害剤
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
CA3214172A1 (en) * 2021-04-02 2022-10-06 Mukesh K. Nyati Combination therapy for cancer treatment
WO2023003417A1 (ko) * 2021-07-22 2023-01-26 국립암센터 Kras 돌연변이 특이적 저해제 및 이를 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
CA2612183C (en) * 2005-06-28 2015-08-11 Genentech, Inc. Egfr and kras mutations
WO2010114922A1 (en) * 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
WO2012064642A1 (en) * 2010-11-08 2012-05-18 Glaxosmithkline Llc Fatty acid synthase inhibitors
US20140256767A1 (en) 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
WO2014176475A2 (en) 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof
EP3755323A4 (en) * 2018-02-23 2021-11-24 The Regents Of The University Of Michigan EGFR DIMER DISRUPTORS AND THEIR USES

Also Published As

Publication number Publication date
WO2021034992A1 (en) 2021-02-25
AU2020334069A1 (en) 2022-03-24
IL290454B2 (en) 2025-12-01
CN114286676A (zh) 2022-04-05
EP4017489B1 (en) 2025-05-07
JP2022545005A (ja) 2022-10-24
BR112022003165A2 (pt) 2022-05-17
AU2020334069B2 (en) 2026-02-19
IL290454A (en) 2022-04-01
JP7602272B2 (ja) 2024-12-18
KR20220050143A (ko) 2022-04-22
CA3150759A1 (en) 2021-02-25
IL290454B1 (en) 2025-08-01
EP4017489A4 (en) 2023-08-23
EP4017489C0 (en) 2025-05-07
US20220273643A1 (en) 2022-09-01
MX2022002108A (es) 2022-03-17
EP4017489A1 (en) 2022-06-29

Similar Documents

Publication Publication Date Title
CN119454706A (zh) 治疗kras相关癌症的方法
EP3355926B1 (en) Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using
AU2016213972B2 (en) Combinations of IRS/Stat3 dual modulators and anti-cancer agents for treating cancer
US10350213B2 (en) Methods for treating cancer using apilimod
CN115768423A (zh) Egfr、kras、braf和其他靶标的抑制剂及其用途
CN115397413A (zh) Egfr、kras、braf和其他靶标的抑制剂及其用途
KR101668931B1 (ko) 항종양제의 효과 증강제
JP2016535756A (ja) ブロモドメインおよびエクストラターミナル（ｂｅｔ）タンパク質インヒビターを使用するがんのための併用療法
EA028452B1 (ru) Лечение рака молочной железы
JP2017503842A (ja) 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
CN105120868A (zh) 组合治疗
TW201908317A (zh) 使用parp抑制劑、替莫唑胺及/或放射療法的組合治療癌症
WO2009109605A1 (en) Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
JP2019519573A (ja) がんを処置するための方法
TW202535405A (zh) 用於藉由增強數類已核准藥物的作用以治療癌症之alc1抑制劑
EP3854396A1 (en) Quinoline derivative used for treating small cell lung cancer
HK40072817A (en) Method of treating kras-associated cancers
US20240252490A1 (en) Combination Therapies Comprising Kras Inhibitors and SPH2 Inhibitors
WO2016197981A1 (zh) 氘代的3-[(6-喹啉基)二氟甲基]-6-[(1-甲基)-4-吡唑基][1,2,4]三唑并[4,3-b]哒嗪及其应用
HK40055928A (en) Quinoline derivative used for treating small cell lung cancer
BR112017016776B1 (pt) Composição e combinação farmacêutica compreendendo um composto d, um inibidor de egfr e/ou um anticorpo egfr
HK1254258B (en) Methods for treating cancer using apilimod

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination